Order Article Reprints

Takahashi T, Ishida K, Emi Y, Sakamoto M, Imura J, Aishima S, Muro K, Uetake H, Oki E, Katayose Y, et al. Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. Cancers. 2022; 14(18):4392. https://doi.org/10.3390/cancers14184392

Takahashi, Takao, Kazuyuki Ishida, Yasunori Emi, Michiie Sakamoto, Johji Imura, Shinichi Aishima, Kei Muro, Hiroyuki Uetake, Eiji Oki, Yu Katayose, and et al. 2022. "Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial" Cancers 14, no. 18: 4392. https://doi.org/10.3390/cancers14184392

Takahashi, T., Ishida, K., Emi, Y., Sakamoto, M., Imura, J., Aishima, S., Muro, K., Uetake, H., Oki, E., Katayose, Y., Yoshida, K., Unno, M., Hyodo, I., Tomita, N., Sugihara, K., & Maehara, Y. (2022). Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial. Cancers, 14(18), 4392. https://doi.org/10.3390/cancers14184392